No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
www.kyorin-pharm.co.jpNo one on the platform currently holds 4569.T.
No tracked institution reports a position in 4569.T as of their last filing.
No one on the platform has traded 4569.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.8% | 3.4% | 4.3% | — | — | — |
| Rev. Growth % | -2.9% | 4.2% | ||||
| Profit Margin % | 2.7% | 4.4% | 5.2% | |||
| Free Cash Flow Margin % | 2.0% | -0.7% | 1.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $121.8B | -3.4% | $30.70 | $30.70–$30.70 | — | 1 |
| 2028 | $107.1B | -12.1% | $15.90 | $15.90–$15.90 | — | 1 |
| 2029 | $114.9B | +7.3% | $53.20 | $53.20–$53.20 | — | 1 |
| 2030 | $120.3B | +4.7% | $74.00 | $74.00–$74.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.22% |
| $74.5B |
| — |
| 4552.TJCR Pharmaceuticals Co., Ltd. | $516.00 | -0.58% | $63.0B | — |
| 4559.TZeria Pharmaceutical Co., Ltd. | $2014.00 | -0.10% | $88.8B | — |
Source: Financial Modeling Prep · peers by sector/industry